Chrissy Morgenthaler, MS, MBA, is a member of the VWD Connect Foundation Research Committee, co-PI of the Severe VWD Patient Registry, and is diagnosed with Type 3 VWD. She is also a seasoned clinical trials professional with over 9 years of experience in roles at site, vendor, and Sponsor levels of research. Her therapeutic experience is in cardiology, oncology, rare diseases, inflammatory diseases, and dermatology.
Chrissy is currently the Associate Director of Clinical Operations at InCarda Therapeutics, managing cardiac clinical trials in atrial fibrillation. Previously she held positions at Gilead Sciences, BioMarin, QuantifiCare, and UCLA.
Chrissy holds a BS in Geology from San Jose State University, an MS in Biotechnology with a concentration in Protein Bioinformatics from Johns Hopkins University, and an MBA from Quantic School of Business and Technology.